More frequently reported side effects include: injection site reaction.  See below for a comprehensive list of adverse effects.
Applies to mepolizumab: subcutaneous powder for solution
In addition to its needed effects, some unwanted effects may be caused by mepolizumab. In the event that any of these side effects do occur, they may require medical attention.

If any of the following side effects occur while taking mepolizumab, check with your doctor or nurse immediately:
Some of the side effects that can occur with mepolizumab may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:


Applies to mepolizumab: subcutaneous powder for injection
The more commonly reported side effects were headache, injection site reactions, and back pain.[Ref]
Dizziness occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.[Ref]
Very common (10% or more): Headache (up to 19%)Frequency not reported: Dizziness[Ref]
Common (1% to 10%): Systemic non-allergic/administration-related reactions (including rash, flushing, myalgia), systemic/hypersensitivity reactions (including rash, pruritus, headache, myalgia)Frequency not reported: Allergic rhinitis, angioedema, urticaria[Ref]
Many systemic reactions occurred on the day of dosing.  Systemic reactions occurred in 10% of patients treated with this drug compared to 7% of placebo-treated patients.  Non-allergic reactions occurred in 2% of patients given this drug versus 3% of patients with placebo; allergic systemic reactions occurred in 1% and 2% of patients given this drug or placebo, respectively.Allergic rhinitis occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.[Ref]
Common (1% to 10%): Injection site reactions (e.g., pain, swelling, erythema, itching, burning)[Ref]
Injection site reactions occurred in 8% and 3% of patients given this drug or placebo, respectively.  The reactions more commonly occurred within the first 3 injections, with a decrease in frequency on subsequent injections.[Ref]
In a clinical trial, 6% of patients developed anti-mepolizumab antibodies; these antibodies were shown to slightly increase drug clearance, but the clinical relevance is unknown.Viral infection occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.[Ref]
Common (1% to 10%): Influenza, anti-mepolizumab antibody formationFrequency not reported: Viral infection[Ref]
Common (1% to 10%): Pruritus, eczemaFrequency not reported: Rash, flushing, herpes zoster reaction[Ref]
Rash and herpes zoster occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.[Ref]
Common (1% to 10%): Back pain, muscle spasmsFrequency not reported: Musculoskeletal pain, myalgia[Ref]
Musculoskeletal pain occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.[Ref]
Gastroenteritis, abdominal pain, nausea, toothache, and vomiting occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.[Ref]
Common (1% to 10%): Upper abdominal painFrequency not reported: Gastroenteritis, abdominal pain, nausea, toothache, vomiting[Ref]
Common (1% to 10%): Fatigue, pyrexiaFrequency not reported: Asthenia, ear infection[Ref]
Asthenia, ear infection, and pyrexia occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.[Ref]
Common (1% to 10%): Urinary tract infection[Ref]
Bronchitis, dyspnea, lower respiratory tract infection, nasal congestion, nasopharyngitis, pharyngitis, and viral respiratory tract infection occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.[Ref]
Common (1% to 10%): Lower respiratory tract infection, pharyngitis, nasal congestionFrequency not reported: Bronchitis, dyspnea, nasopharyngitis, viral respiratory tract infection, bronchospasm[Ref]
Frequency not reported: Hypotension[Ref]
Frequency not reported: Cystitis[Ref]
Cystitis occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.[Ref]
1. "Product Information. Nucala (mepolizumab)." GlaxoSmithKline, Research Triangle Park, NC. 
2. Cerner Multum,  Inc. "Australian Product Information." O 0
3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
Not all side effects for mepolizumab may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Blurred vision
confusion
cough
difficulty with breathing
dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
hives or welts, itching, or skin rash
large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
noisy breathing
painful blisters on the trunk of the body
redness of the skin
sweating
tightness in the chest
unusual tiredness or weakness


Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
headache


Back pain
bladder pain
bloody or cloudy urine
chills
cough
diarrhea
difficult, burning, or painful urination
fever
frequent urge to urinate
general feeling of discomfort or illness
joint pain
loss of appetite
lower back or side pain
muscle aches and pains
muscle spasms
nausea
runny nose
shivering
skin rash, encrusted, scaly, and oozing
sore throat
sweating
trouble sleeping
upper abdominal or stomach pain
vomiting

